New drug combo aims to wipe out hidden breast cancer cells
NCT ID NCT07191717
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests two drugs, imlunestrant and abemaciclib, in people with ER+ breast cancer who have small amounts of tumor DNA still in their blood after initial treatment. The goal is to see if this combination can clear those remaining cancer traces and prevent the cancer from coming back. About 42 participants with stage I-III breast cancer will take the drugs for up to 12 cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.